5 Results for "

Adezmapimod

" in MedChemExpress (MCE) Product Catalog:
Products (5)

5 Results for "Adezmapimod" in MCE Product Catalog:

626
626 Publications Verification
Cat. No.: HY-10256
CAS No.: 152121-47-6
Purity:  99.92%
Synonyms: SB 203580; RWJ 64809
Adezmapimod (SB 203580) is a selective and ATP-competitive p38 MAPK inhibitor with IC50s of 50 nM and 500 nM for SAPK2a/p38 and SAPK2b/p38β2, respectively. Adezmapimod inhibits LCK, GSK3β and PKBα with IC50s of 100-500-fold higher than that for SAPK2a/p38. Adezmapimod can inhibit p38 MAPK and lead to the inhibition of downstream HSP27 phosphorylation. Adezmapimod does not disrupt JNK activity and is an autophagy and mitophagy activator .
loading...
    loading...
626
626 Publications Verification
Cat. No.: HY-10256A
CAS No.: 869185-85-3
Purity:  99.37%
Synonyms: SB 203580 hydrochloride; RWJ 64809 hydrochloride
Adezmapimod (SB 203580; RWJ 64809) hydrochloride is a selective and ATP-competitive p38 MAPK inhibitor with IC50s of 50 nM and 500 nM for SAPK2a/p38 and SAPK2b/p38β2, respectively. Adezmapimod hydrochloride inhibits LCK, GSK3β and PKBα with IC50s of 100-500-fold higher than that for SAPK2a/p38. Adezmapimod hydrochloride does not disrupt JNK activity and is an autophagy and mitophagy activator .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-118034
CAS No.: 1110905-26-4
Purity:  99.60%
Target:  

p38 MAPK Apoptosis

Research Areas:  

Cancer

MTBT is an anticancer agent and p38 MAPK activator. MTBT can inhibit tumor cell proliferation, induce cell cycle arrest and apoptosis. MTBT increases the phosphorylation of histone H3 serine in cancer cells, thereby arresting the cell cycle in the M phase. The specific inhibitor of p38 MAPK, Adezmapimod (HY-10256), can abrogate the cell cycle arrest induced by MTBT .
loading...
    loading...
Cat. No.: HY-10256R
CAS No.: 152121-47-6
Synonyms: SB 203580 (Standard); RWJ 64809 (Standard)
Adezmapimod (Standard) is the analytical standard of Adezmapimod. This product is intended for research and analytical applications. Adezmapimod (SB 203580) is a selective and ATP-competitive p38 MAPK inhibitor with IC50s of 50 nM and 500 nM for SAPK2a/p38 and SAPK2b/p38β2, respectively. Adezmapimod inhibits LCK, GSK3β and PKBα with IC50s of 100-500-fold higher than that for SAPK2a/p38. Adezmapimod can inhibit p38 MAPK and lead to the inhibition of downstream HSP27 phosphorylation. Adezmapimod does not disrupt JNK activity and is an autophagy and mitophagy activator .
loading...
    loading...
Cat. No.: HY-10256AR
CAS No.: 869185-85-3
Synonyms: SB 203580 hydrochloride (Standard); RWJ 64809 hydrochloride (Standard)
Adezmapimod (hydrochloride) (Standard) is the analytical standard of Adezmapimod (hydrochloride). This product is intended for research and analytical applications. Adezmapimod (SB 203580; RWJ 64809) hydrochloride is a selective and ATP-competitive p38 MAPK inhibitor with IC50s of 50 nM and 500 nM for SAPK2a/p38 and SAPK2b/p38β2, respectively. Adezmapimod hydrochloride inhibits LCK, GSK3β and PKBα with IC50s of 100-500-fold higher than that for SAPK2a/p38. Adezmapimod hydrochloride does not disrupt JNK activity and is an autophagy and mitophagy activator .
loading...
    loading...